Welcome to BioLogical – MedImmune’s blog that offers readers a peek into our innovative science, inspiring employees and communities in which we support. . What does the name mean? By definition, biological means “of, relating to, caused by, or affecting life or living organisms.” The ultimate goal of our science is to deliver life-changing medicines to patients but that’s not the only way we affect lives. As the global biologics research and development arm of AstraZeneca, we are able to combine their worldwide presence with our distinct and unique culture, as we continue to solve global healthcare challenges and redefine science.
We want this blog to be a forum where you can interact with the people of MedImmune and gain insight into why we do what we do. We welcome your feedback, comments and questions and will work to answer them as quickly as we can. Check out our house rules for more information.
I’m proud to introduce BioLogical during this very special week. MedImmune turns a quarter century this year and we’re celebrating all week with fun employee events and charitable donations. Want to see what we’ve accomplished in the last 25 years? Visit our interactive history timeline.
Here are 10 reasons we’re celebrating turning 25:
- Our people – We are driven by the desire to develop innovative medicines that bring hope to patients and improve lives. We aim to positively impact the world through extraordinary science, and approach our jobs with the passion, innovation, and rigor it takes to be a revolutionary force in biotech. Sound like a place you’d like to work?
- Our science – We focus on therapeutic proteins, monoclonal antibodies, and other next-generation molecules to attack a range of diseases, – putting us at the forefront of biologics research and development. Our research organization is accountable for disease biology and target discovery, predictive sciences, safety and toxicology, early biomarker and patient stratification research, drug discovery, and pre-clinical drug development.
- Our therapeutic areas – We focus on three core areas – respiratory, inflammation, autoimmunity; cardiovascular and metabolic disease, and oncology; we’re also opportunity-driven in infection & vaccines and neuroscience.
- Our pipeline – We have a very robust pipeline – with more than 120 biologics in research and development and more than 30 projects in clinical stage development, making up about 50% of AstraZeneca’s overall pipeline.
- Our technologies – When it comes to breakthroughs in biotechnology research, MedImmune is a visionary company that is helping shape the industry. We have become leaders in therapeutic antibodies by developing a broad suite of antibody identification, optimization, engineering, characterization, and expression platforms.
- Our ability to make a difference - As part of our enduring commitment to the community, MedImmune gives annually to non-profit organizations through our mission-aligned philanthropy program. In celebration of our 25th anniversary, we will donate $25,000 to organizations that work in our two priority areas -- science education and healthcare.
- Our perseverance - We aim high, and as a result we expect a lot of each other and ourselves. Candor and transparency are essential at all times, and we are willing to challenge ourselves if that gets us closer to the right solution for patients.
- Our culture – We’ve got a strong sense of camaraderie and collaboration with an appetite for working hard and playing hard. Although we’re growing in size, we maintain our entrepreneurial spirit.
- Our global footprint – While we’re headquartered in Gaithersburg, Maryland, our footprint stretches far beyond. Two of AstraZeneca’s three global R&D centers are at MedImmune sites in Cambridge, UK and Gaithersburg. We also have a presence in California and those facilities help support pharmacology analytics (pharmacokinetics/pharmacodynamics) and clinical and non-clinical sample and data management for the entire MedImmune pipeline.
- Our future – While we look back with pride to our last 25 years, we’re full of hope for the next 25. As long as there are patients with unmet medical needs, our scientists will be working hard to find solutions. We’re excited for what the future holds.